Caspian Therapeutics, Inc. — SEC Form D Filing

Caspian Therapeutics, Inc. filed an SEC Form D on September 23, 2026, reporting $50.00M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 23, 2026
Amount reported
$50.00M
Round stage
Series B+
Industry
Biotechnology
Website
https://kuraoncology.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Many cancer patients do not benefit from current precision medicines, or their disease returns due to treatment resistance. There is an unmet need for effective, durable treatments for cancer.

Solution

The company discovers and develops novel, targeted cancer therapeutics designed to selectively attack cancer cells and overcome treatment resistance, with the goal of providing long-lasting remissions.

Why now

Advances in molecular understanding of cancer and precision medicine technologies allow for the development of highly targeted therapies, moving beyond broad-spectrum treatments.

Verdict

Investors funded Caspian because the oncology market continued to reward validated precision medicine approaches for unmet needs, not because they saw a breakthrough in therapeutic modality itself. They were implicitly betting on the team's ability to navigate clinical trials and regulatory pathways for a well-understood drug class, coupled with the existing appetite for acquisition targets in oncology. The upside was capped by the inherent clinical development risks and the typical valuation multiples for assets at this stage, rather than a novel platform creating entirely new markets.

Source: SEC EDGAR Form D filing